Erythropoietin (EPO) is a hematopoietic signaling factor for survival and differentiation which increased FXN levels in FRDA patient lymphocytes, mobilizes iron to heme, and exhibits some neuro- and cardioprotective capacity, suggesting its use in clinical trials (Boesch et al., 2007). This evidence concerns the gene FXN and Friedreich ataxia.